Treatment of prediabetes by gliflozins: Risk of infection by Ali Shayanfar

Get full text

Standardized Chromatographic and Computational Approaches for Lipophilicity Analysis of Five Gliflozin Antidiabetic Drugs in Relation to Their Biological Activity by Anna Gumieniczek, Anna Berecka-Rycerz, Marcelina Dul, Aleksandra Pryjda

Subjects: “…gliflozins…”
Get full text

Evaluating the overall renal outcomes of sodium-glucose cotransporter-2 (SGLT2) inhibitors in patients with chronic kidney disease (CKD) by Min-Jia Cao, Ting-Ting Liang, Li Xu, Fang-Hong Shi

“…We selected medical subject heading (MeSH) terms and free text terms associated with gliflozin and RCT. We calculated odds ratio (OR) or harzard ratio with 95% confidence intervals (CIs) for composite outcomes and dichotomous data, and weighted mean differences (WMD) for changes in eGFR. …”
Get full text

Study of cardiovascular risk in type 2 diabetic patients in the acute phase of the coronavirus infection and post-COVID period on the background of therapy with sodium-glucose cotr... by N.M. Kushnarоva, O.V. Zinych, A.A. Shuprovych, K.P. Komisarenko

“…The results obtained confirm the positive effect of taking SGLT2i on the level of cardiovascular risk markers in patients with T2DM who had received gliflozin therapy for 9 months after recovery from COVID-19, in contrast to the group of patients who received metformin/sulfonylurea derivatives.…”
Get full text

Sodium‐glucose cotransporter‐2 inhibitors in heart failure: an updated meta‐analysis by Yang Cao, Pengxiao Li, Yi Li, Yaling Han

“…Compared with placebo, SGLT2i is associated with a lower incidence of composite of first hospitalization for heart failure (HHF) or cardiovascular death (CV death) [hazard ratio (HR) = 0.76 95% confidence interval (CI) = 0.71–0.81], which is consistent regardless of the diabetes status, type of gliflozines used, and follow‐up duration. SGLT2i can reduce the risk of total HHF or CV death (HR = 0.74, 95%CI = 0.68–0.81), first HHF (HR = 0.69, 95%CI = 0.64–0.75), CV death (HR = 0.88, 95%CI = 0.80–0.96), any death (HR = 0.90, 95%CI = 0.83–0.97), and any serious events (HR = 0.90, 95%CI = 0.87–0.93) in HF patients, at the cost of increased risk of urinary tract infections (risk ratio = 1.17, 95%CI = 1.03–1.33). …”
Get full text